Anti-Depressant Drugs Market 2027 By Depression Disorder, Product and Geography | The Insight Partners

Anti-Depressant Drugs Market to 2027 - Global Analysis and Forecasts By Depression Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others); Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine reuptake Inhibitors, Monoamine oxidase inhibitors, Serotonin antagonist and reuptake inhibitors, Others)and Geography

Report Code: TIPRE00007249 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION

Anti-depressant drugs is a class of medications which is used to treat major depressive disorder, some anxiety disorders, some chronic pain conditions, and to help manage some addictions. Anti-depressant drugs also reduce symptoms of depressive disorders by correcting chemical imbalances of neurotransmitters in the brain. Chemical imbalances may be responsible for changes in mood and behavior.

MARKET DYNAMICS

Anti-depressant drugs market is anticipated to grow in the forecast period owing to driving factors such as growing prevalence of depression, rising geriatric population, and emergence of novel techniques for the development of drugs. Moreover, rising investments in R&D by the public and private sector, and increase in number of patent expiration of antidepressants are also offering opportunities in the market growth during the forecast period.

MARKET SCOPE

The "Global Anti-Depressant Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of anti-depressant drugs market with detailed market segmentation by product, depression disorder, and geography. The global anti-depressant drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading anti-depressant drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global anti-depressant drugs market is segmented on the basis of product and depressive disorder. Based on product, the market is segmented as tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, and others. Based on depressive disorder, the market is segmented as major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others.

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global anti-depressant drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The anti-depressant drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting anti-depressant drugs market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the anti-depressant drugs market in these regions.

MARKET PLAYERS


The report covers key developments in the anti-depressant drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from anti-depressant drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for anti-depressant drugs in the global market. Below mentioned is the list of few companies engaged in the Analgesics market.

The report also includes the profiles of key anti-depressant drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  •  Alkermes Plc,
  •  Allergan Plc,
  •  Bristol Myers Squibb Co.
  •  Eli Lilly and Co.
  •  GlaxoSmithKline Plc
  •  H. Lundbeck
  •  Merck & Co., Inc.
  •  Pfizer Inc.
  •  Teva Pharmaceutical Industries Ltd.
  •  Takeda Pharmaceutical Co. Ltd.

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti-depressant Drugs Market - By Depression Disorder
1.3.2 Anti-depressant Drugs Market - By Product
1.3.3 Anti-depressant Drugs Market - By Region
1.3.3.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. ANTI-DEPRESSANT DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. ANTI-DEPRESSANT DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. ANTI-DEPRESSANT DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTI-DEPRESSANT DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTI-DEPRESSANT DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. ANTI-DEPRESSANT DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DEPRESSION DISORDER
7.1. OVERVIEW
7.2. DEPRESSION DISORDER MARKET FORECASTS AND ANALYSIS
7.3. MAJOR DEPRESSIVE DISORDER
7.3.1. Overview
7.3.2. Major Depressive Disorder Market Forecast and Analysis
7.4. OBSESSIVE-COMPULSIVE DISORDER
7.4.1. Overview
7.4.2. Obsessive-Compulsive Disorder Market Forecast and Analysis
7.5. GENERALIZED ANXIETY DISORDER
7.5.1. Overview
7.5.2. Generalized Anxiety Disorder Market Forecast and Analysis
7.6. PANIC DISORDER
7.6.1. Overview
7.6.2. Panic Disorder Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. ANTI-DEPRESSANT DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - PRODUCT
8.1. OVERVIEW
8.2. PRODUCT MARKET FORECASTS AND ANALYSIS
8.3. TRICYCLIC ANTIDEPRESSANTS
8.3.1. Overview
8.3.2. Tricyclic Antidepressants Market Forecast and Analysis
8.4. SELECTIVE SEROTONIN REUPTAKE INHIBITORS
8.4.1. Overview
8.4.2. Selective Serotonin Reuptake Inhibitors Market Forecast and Analysis
8.5. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
8.5.1. Overview
8.5.2. Serotonin-norepinephrine reuptake Inhibitors Market Forecast and Analysis
8.6. MONOAMINE OXIDASE INHIBITORS
8.6.1. Overview
8.6.2. Monoamine oxidase inhibitors Market Forecast and Analysis
8.7. SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS
8.7.1. Overview
8.7.2. Serotonin antagonist and reuptake inhibitors Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. ANTI-DEPRESSANT DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Anti-depressant Drugs Market Overview
9.1.2 North America Anti-depressant Drugs Market Forecasts and Analysis
9.1.3 North America Anti-depressant Drugs Market Forecasts and Analysis - By Depression Disorder
9.1.4 North America Anti-depressant Drugs Market Forecasts and Analysis - By Product
9.1.5 North America Anti-depressant Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Anti-depressant Drugs Market
9.1.5.1.1 United States Anti-depressant Drugs Market by Depression Disorder
9.1.5.1.2 United States Anti-depressant Drugs Market by Product
9.1.5.2 Canada Anti-depressant Drugs Market
9.1.5.2.1 Canada Anti-depressant Drugs Market by Depression Disorder
9.1.5.2.2 Canada Anti-depressant Drugs Market by Product
9.2. EUROPE
9.2.1 Europe Anti-depressant Drugs Market Overview
9.2.2 Europe Anti-depressant Drugs Market Forecasts and Analysis
9.2.3 Europe Anti-depressant Drugs Market Forecasts and Analysis - By Depression Disorder
9.2.4 Europe Anti-depressant Drugs Market Forecasts and Analysis - By Product
9.2.5 Europe Anti-depressant Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Anti-depressant Drugs Market
9.2.5.1.1 Germany Anti-depressant Drugs Market by Depression Disorder
9.2.5.1.2 Germany Anti-depressant Drugs Market by Product
9.2.5.2 France Anti-depressant Drugs Market
9.2.5.2.1 France Anti-depressant Drugs Market by Depression Disorder
9.2.5.2.2 France Anti-depressant Drugs Market by Product
9.2.5.3 Italy Anti-depressant Drugs Market
9.2.5.3.1 Italy Anti-depressant Drugs Market by Depression Disorder
9.2.5.3.2 Italy Anti-depressant Drugs Market by Product
9.2.5.4 Spain Anti-depressant Drugs Market
9.2.5.4.1 Spain Anti-depressant Drugs Market by Depression Disorder
9.2.5.4.2 Spain Anti-depressant Drugs Market by Product
9.2.5.5 United Kingdom Anti-depressant Drugs Market
9.2.5.5.1 United Kingdom Anti-depressant Drugs Market by Depression Disorder
9.2.5.5.2 United Kingdom Anti-depressant Drugs Market by Product
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Anti-depressant Drugs Market Overview
9.3.2 Asia-Pacific Anti-depressant Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Anti-depressant Drugs Market Forecasts and Analysis - By Depression Disorder
9.3.4 Asia-Pacific Anti-depressant Drugs Market Forecasts and Analysis - By Product
9.3.5 Asia-Pacific Anti-depressant Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Anti-depressant Drugs Market
9.3.5.1.1 Australia Anti-depressant Drugs Market by Depression Disorder
9.3.5.1.2 Australia Anti-depressant Drugs Market by Product
9.3.5.2 China Anti-depressant Drugs Market
9.3.5.2.1 China Anti-depressant Drugs Market by Depression Disorder
9.3.5.2.2 China Anti-depressant Drugs Market by Product
9.3.5.3 India Anti-depressant Drugs Market
9.3.5.3.1 India Anti-depressant Drugs Market by Depression Disorder
9.3.5.3.2 India Anti-depressant Drugs Market by Product
9.3.5.4 Japan Anti-depressant Drugs Market
9.3.5.4.1 Japan Anti-depressant Drugs Market by Depression Disorder
9.3.5.4.2 Japan Anti-depressant Drugs Market by Product
9.3.5.5 South Korea Anti-depressant Drugs Market
9.3.5.5.1 South Korea Anti-depressant Drugs Market by Depression Disorder
9.3.5.5.2 South Korea Anti-depressant Drugs Market by Product
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Anti-depressant Drugs Market Overview
9.4.2 Middle East and Africa Anti-depressant Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Anti-depressant Drugs Market Forecasts and Analysis - By Depression Disorder
9.4.4 Middle East and Africa Anti-depressant Drugs Market Forecasts and Analysis - By Product
9.4.5 Middle East and Africa Anti-depressant Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Anti-depressant Drugs Market
9.4.5.1.1 South Africa Anti-depressant Drugs Market by Depression Disorder
9.4.5.1.2 South Africa Anti-depressant Drugs Market by Product
9.4.5.2 Saudi Arabia Anti-depressant Drugs Market
9.4.5.2.1 Saudi Arabia Anti-depressant Drugs Market by Depression Disorder
9.4.5.2.2 Saudi Arabia Anti-depressant Drugs Market by Product
9.4.5.3 U.A.E Anti-depressant Drugs Market
9.4.5.3.1 U.A.E Anti-depressant Drugs Market by Depression Disorder
9.4.5.3.2 U.A.E Anti-depressant Drugs Market by Product
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Anti-depressant Drugs Market Overview
9.5.2 South and Central America Anti-depressant Drugs Market Forecasts and Analysis
9.5.3 South and Central America Anti-depressant Drugs Market Forecasts and Analysis - By Depression Disorder
9.5.4 South and Central America Anti-depressant Drugs Market Forecasts and Analysis - By Product
9.5.5 South and Central America Anti-depressant Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Anti-depressant Drugs Market
9.5.5.1.1 Brazil Anti-depressant Drugs Market by Depression Disorder
9.5.5.1.2 Brazil Anti-depressant Drugs Market by Product
9.5.5.2 Argentina Anti-depressant Drugs Market
9.5.5.2.1 Argentina Anti-depressant Drugs Market by Depression Disorder
9.5.5.2.2 Argentina Anti-depressant Drugs Market by Product
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ANTI-DEPRESSANT DRUGS MARKET, KEY COMPANY PROFILES
11.1. ALKERMES PLC
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ALLERGAN PLC
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BRISTOL MYERS SQUIBB CO.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ELI LILLY AND CO.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. GLAXOSMITHKLINE PLC
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. H. LUNDBECK
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. MERCK AND CO., INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. PFIZER INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. TAKEDA PHARMACEUTICAL CO. LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Alkermes Plc,
2. Allergan Plc,
3. Bristol Myers Squibb Co.
4. Eli Lilly and Co.
5. GlaxoSmithKline Plc
6. H. Lundbeck
7. Merck & Co., Inc.
8. Pfizer Inc.
9. Teva Pharmaceutical Industries Ltd.
10. Takeda Pharmaceutical Co. Ltd.